ADAR1 Capital Management LLC Acquires Shares of 8,000 Establishment Labs Holdings Inc. $ESTA

Key Points

• ADAR1 Capital Management LLC has invested $326,000 in Establishment Labs Holdings Inc. by acquiring 8,000 shares in the first quarter.
• Several hedge funds have also engaged with Establishment Labs, contributing to a total of 72.91% institutional ownership of the stock.
• Wall Street analysts generally maintain a Moderate Buy consensus rating for Establishment Labs, with a target price of $56.50, although recent earnings reports highlighted a miss in EPS estimates.

ADAR1 Capital Management LLC bought a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,000 shares of the company's stock, valued at approximately $326,000.

A number of other institutional investors also recently bought and sold shares of ESTA. Quarry LP bought a new stake in Establishment Labs during the 4th quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Establishment Labs in the 1st quarter valued at approximately $81,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Establishment Labs during the first quarter valued at approximately $207,000. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Establishment Labs during the first quarter valued at approximately $234,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Establishment Labs in the 1st quarter worth about $894,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Performance

Shares of Establishment Labs stock traded up $0.36 during trading hours on Friday, reaching $39.03. 173,812 shares of the stock traded hands, compared to its average volume of 392,709. The company has a 50 day moving average price of $41.41 and a 200 day moving average price of $37.91. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $50.85. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.80 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million for the quarter, compared to analysts' expectations of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The company's revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on ESTA shares. Wall Street Zen downgraded shares of Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Canaccord Genuity Group began coverage on shares of Establishment Labs in a report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research note on Friday, June 13th. BTIG Research initiated coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Finally, Mizuho upped their price target on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $56.50.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.